Casdin Capital’s Genomic Health, Inc. GHDX Stock Holding History

Casdin Capital’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-90,000	Closed	-$2.6M	–	30
2016 Q3	$2.6M	Buy	+90,000	New	+$2.51M	2.11%	19
2016 Q2	–	Sell	-55,000	Closed	-$1.36M	–	33
2016 Q1	$1.36M	Sell	55,000 -110,000	-67%	-$3.02M	1.56%	19
2015 Q4	$5.81M	Buy	+165,000	New	+$4.42M	5.13%	9

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Casdin Capital's GHDX Position: Q4 2016 in Review

Casdin Capital sold out of Genomic Health, Inc. (GHDX) in Q4 2016, closing a stake of 90,000 shares — an estimated $2.6M sold.

Casdin Capital first reported a position in GHDX in Q4 2015 and held it in 3 quarters. The position peaked at $5.81M in Q4 2015. 133 funds tracked by Wall St. Rank hold GHDX as of Q4 2016.

Casdin Capital reported no remaining Genomic Health, Inc. position as of Q4 2016 after selling out during the quarter.
Casdin Capital sold 90,000 Genomic Health, Inc. shares in Q4 2016, an estimated $2.6M.
Casdin Capital first reported a position in Genomic Health, Inc. in Q4 2015 and held it in 3 quarters.
Casdin Capital's Genomic Health, Inc. position peaked at $5.81M in Q4 2015.
133 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2016.

Based on Casdin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.